Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
3 hedge funds and large institutions have $16.6M invested in Seelos Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $17.6M → $16.6M (-$1.04M)
18% less call options, than puts
Call options by funds: $164K | Put options by funds: $199K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$79K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$73K |
| 3 |
Millennium Management
New York
|
-$54K |
| 4 |
EEG
E.E. Geduld
|
-$47K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HDIM
26
Hanson & Doremus Investment Management
Burlington,
Vermont
| $2K | – | – | – |
|
|
ST
27
Sphinx Trading
Chicago,
Illinois
| $2K | – | – | – |
|
28
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
|
LTFS
29
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
30
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $7 | – | – | – |
|
|
31
Creative Planning
Overland Park,
Kansas
| – | -$11K | – | – |
|
|
EEG
32
E.E. Geduld
| – | -$47K | – | – |
|
|
33
HighTower Advisors
Chicago,
Illinois
| – | -$73K | – | – |
|
|
34
Millennium Management
New York
| – | -$54K | – | – |
|
|
RCM
35
Rotella Capital Management
Bellevue,
Washington
| – | -$79K | – | – |
|
SEEL Hedge Fund Activity: Q2 2015 in Review
3 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2015, worth a combined $16.6M — down 5.9% from $17.6M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SEEL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Healthcare Value Capital, opening a new position worth an estimated $1.91M. The largest seller was Rotella Capital Management, cutting an estimated $79K.
- 3 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2015, up from 2 in Q1 2015.
- Funds reported $16.6M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2015, down 5.9% quarter-over-quarter.
- 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2015 and 0 closed out, a net change of +1 holder.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2015 was Healthcare Value Capital, an estimated $1.91M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2015 was Rotella Capital Management, an estimated $79K sold.
Based on aggregated 13F filings for Q2 2015.